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ABSTRACT
Introduction: MDM2 and MDMX proteins provide the inhibition of p53 tumor suppressor, thus allowing
for accelerated mutation-driven cancer microevolution. A pharmacological blockade of MDM2/X-p53
interaction results in p53 reactivation in p53wt cells, leading to cancer growth inhibition. Throughout
the past 20 years, multiple chemical entities have been proposed to reactivate p53 by antagonizing
MDM2/X proteins.
Areas covered: This manuscript reviews 2014–2018 therapeutic patents in the field of MDM2/X
antagonists and is a continuation of previous reviews on similar matter. The patents covering the use
of MDM2/X antagonists in drug combinations are also presented in this review, as they constitute an
important trend in the field of cancer treatment with MDM2/X antagonists.
Expert opinion: In the years 2014–2018, several previously-known chemical scaffolds have been further
developed and disclosed. Importantly, in the same time period, many lead compounds have entered
clinical trials for the treatment of cancer patients. Meanwhile, several important reports have pointed to
serious limitations of anticancer properties of MDM2 antagonists. As a result, many efforts have been
made to seek for positive, synergistic therapeutic effects of combined anti-cancer treatment strategies.
One recent example is a dual targeting of MDM2 and additional protein targets by utilizing the PROTAC
technology.
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1. Introduction
Cancer incidence and mortality are continuously growing world-
wide. This alarming trend is observed especially in emerging
economies. According to the World Health Organization, cancer
has become a primary cause of premature mortality in devel-
oped countries, including the United States, Japan, and most of
the European countries [1]. Within the past 50 years, much effort
has been done to develop and improve therapeutic methods to
clinically eradicate cancer, yet with limited success. Among the
four classical pillars of anticancer therapy, targeted therapy has
been favored by pharmaceutical companies.
The tumor suppressor protein p53 became one of such
cancer-related targets, as with time it became clear that in
almost 100% of cancers the functioning of p53 is impaired [2].
The p53 protein is a crucial player engaged in the response to
mutations occurring within genomic DNA, providing genome
stability and thus protecting from early cancerogenic events.
Upon the detection of DNA damage, the activity of p53 is
released. p53 acts as a transcription factor that regulates the
expression of a multitude of target genes responsible for the
induction of cell cycle arrest and DNA repair program, giving
the cell the opportunity to self-heal the DNA-occurring lesions
[3]. Should the repair machinery fail, p53 induces the ultimate
solution, which is the induction of apoptosis in extensively
damaged cells [4]. This versatile strategy enabled and inte-
grated by the p53 protects the organism from the expansion
of DNA-mutated, rebellious cells that could possibly lead to
the cancer development.
Considering the anti-cancer nature of p53, it is not surpris-
ing that the inactivation of p53 is a critical step for the cancer
microevolution. It has been estimated that 50% of cancers
disable the p53 protein by gaining loss-of-function mutations
or deletions in the TP53 gene [5,6]. Importantly, the remaining
50% of cancers still express the wild-type p53 protein (p53wt),
but its activity is blocked by innate regulatory mechanisms,
among which overexpression of MDM2 protein is the most
common way to keep p53wt inactive [2]. The MDM2 protein is
a natural binding partner of p53 and a powerful inhibitor of
p53 functioning. MDM2 binds to p53 masking its transactiva-
tion domain, targets p53 to nuclear export, and directly ubi-
quitinates p53 sending the protein to the proteasomal
degradation [7]. For this reason, blocking the MDM2-p53 inter-
action with MDM2 antagonists has become a promising strat-
egy for the restoration of p53 functioning that could possibly
be used for the treatment of p53wt cancers [2].
The MDMX (MDM4) protein, the homolog of MDM2, is
another p53 binding partner and an additional, important
p53 regulator. The p53-inhibitory function of both MDMX
and MDM2 proteins is similar, though the mechanism of inhi-
bition is distinct, as MDMX does not possess the E3 ligase
activity [8]. Structurally, MDMX and MDM2 have remarkable
similarities, especially in the N-terminal (p53 binding region)
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and C-terminal (RING domain) regions [9]. The two MDM2/X
proteins can form heterodimers, which are believed to be
more stable and active in respect to p53 regulation, than
their monomers [7]. Therefore, simultaneous targeting of
both MDM2 and MDMX may be required for effective antic-
ancer treatment strategies [7,10,11].
During the last years, numerous chemical scaffolds have
been proposed for the design of the MDM2 antagonists. These
include: cis-imidazolines, pyrrolidines, piperidines, and purines,
as well as more complex multi-ring structures, such as spir-
oindolinones and non-small molecule moieties, such as pep-
tides (for the review of 2006–2013 therapeutic patents on
MDM2-antagonizing compounds see [12,13], and [14]). These
core structures are frequently decorated with the substituents
that resemble the three critical amino acid residues of p53 that
are directly engaged in its interaction with the MDM2 protein,
i.e. Phe19, Trp23 and Leu26 [15,16]. The Phe19 side chain is
commonly mimicked by 6-membered aromatic rings; ben-
zene/indole substituents are used to mimic the Trp23 side
chain and branched aliphatic residues or additional 6-mem-
bered rings are used to occupy the Leu26-binding pocket on
the MDM2 protein [17]. Such a structural organization of the
compounds provides a classical three-point binding model,
that has been successfully used for the design of the MDM2
antagonists [18].
Although the mode of binding of p53 to MDMX is very
similar to that of p53 binding to MDM2, with even the same
p53 residues involved, the Leu26 pocket of MDMX is smaller
and a unique hydrophobic area is nearby. Therefore, most of
the MDM2 antagonists discovered so far are not able to effi-
ciently disrupt the MDMX-p53 interaction, and only few sev-
eral examples of dual MDM2/MDMX inhibitors are known,
such as small molecule RO-5963 [19], or stapled peptide
ATSP-7041 [20].
The chemical scaffolds of the MDM2/MDMX antagonists are
continuously developed both by the scholars and big phar-
maceutical companies, resulting in the annual emergence of
new therapeutic patents. Previously, we have provided
a review of the therapeutic patents 2011–2013 [14]. This
review covers the therapeutic patents from the years
2014–2018.
2. Discussion of patents on new MDM2 antagonists
(2014–2018)
2.1. Mono-cyclic ring core structures
2.1.1. 5-member rings: imidazoline derivatives
Among MDM2 antagonists, the nutlins, developed and dis-
closed by Hoffmann-La Roche (Basel, Switzerland), were the
first group of compounds that presented a real bioactivity
both in in vitro and in vivo studies [21]. The nutlins are cis-
imidazolines (Figure 1), where the core central imidazoline
ring is decorated with phenyl-derived substituents, that
resemble a classical three-point interaction of p53 with
MDM2, provided by the three crucial p53 amino acids,
Phe19, Trp23 and Leu26 [15,16]. The most potent representa-
tive of first-generation cis-imidazolines, Nutlin-3 (1), became
a proof-of-concept molecule in demonstrating the anticancer
potential of pharmacological reactivation of p53 by antagoniz-
ing MDM2 protein. Further optimization of Nutlin-3 structure
led to the discovery of RG7112 (2), which presented improved
activity and was the first MDM2 antagonist that entered clin-
ical evaluation [22]. While RG7112 presented sufficient clinical
activity to significantly induce p53 and p21 levels in the
treated liposarcoma patients, serious adverse hematological
effects were observed in most of the treated individuals mak-
ing the long-term treatments schemes challenging [23].
In the year 2014 Hoffmann-La Roche has published one
additional patent, covering further optimization trials of the
cis-imidazoline structures (Table 1) [25]. As in RG7112, in the
compounds covered by the patent, the two 4-chlorophenyl
substituents at the cis configuration on the imidazoline ring
are preserved, together with the two methyl groups at the
same positions, likely representing the optimal frontiers of
the structure optimization at these positions (3). The main
optimization efforts reported in the patent were concen-
trated on the changes in the N-1 and C-2 positions (Figure
1). The N-1 4-(3-methyanesulfonylpropyl)piperazine-1-carbo-
nyl substituent, which was the most striking improvement
made from nutlin-3 to RG7112, has been explored with
aliphatic linkers of different lengths, solubility tags (carboxyl,
amid, sulfonyl groups), or a heterocycle (piperidine) [25].
Another structure variation was the introduction of
a second, substituted sulphonyl group in the phenyl ring
at the C-2 position of imidazoline. The resulting compounds
were subjected to HTRF assay resulting in IC50 constants of
around 5 nM against MDM2 protein and 0.2–6 µM against
MDMX protein [25].
The last patent covering the optimization trial of cis-
imidazoline compounds was disclosed in 2015 by St. Jude
Children’s Research Hospital (Table 1) [26]. The disclosed com-
pounds differ from the nutlins at all substituted positions
within the imidazole ring (4), resulting in the compounds of
improved in vitro properties compared to Nutlin-3. The most
striking difference lies in the halogen positioning and the
diversity of cis-3,4-phenyl substituents of imidazoline, includ-
ing the substitution of one of the phenyl rings to the bioisos-
ter of Trp23: 6-chloroindole (Figure 1). Interestingly, all of the 9
tested compounds present similar, two-three digit nanomolar
binding affinities towards both MDM2 and MDMX proteins,
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Figure 1. Structure and in vitro activity of exemplary MDM2 inhibitors based on a 5 membered ring: cis-imidazoline scaffold. The IC50 value for nutlin 3 was is from
[21] and for RG-7112 from [24].
Table 1. MDM2/X antagonists with monocyclic core structures.
Core structure Target
type of rings the core Assignee/patent No. (2014–2018) MDM2 MDMX Combination Examples Compounds in clinical trials
monocyclic
5-member
cis-imidazoline
Hoffmann-La Roche
US 2014/0140988 A1 [82]
US 2014/0148443 A1 [25]
St. Jude Hospital
WO 2015/184383 A1 [26]
Yes
Yes
Yes
–
Yes
Yes
Yes
–
–
(3)
(4)
RG7112 (2)
pyrrolidine
Roche
US 2015/0157603 A1 [29]
US 2017/0008904 A1 [31]
WO 2016/188935 A1 [83]
Yes
Yes
Yes
–
–
–
Yes
Yes
Yes
(6)
RG7388 (5)
3-pyrrolin-2-one
Adamed Sp. z o.o.
WO 2015/004610 A1 [32] Yes Yes –
(7)
(20) –
6-member
piperidinone (X = C)
morpholinone (X = O)
Amgen Inc.
US 2014/0243372 A1 [33]
US 2014/0364455 A1 [36]
WO 2015/070224 A2 [37]
WO 2014/130470 A1 [34]
WO 2014/151863 A1 [35]
Yes
Yes
Yes
Yes
Yes
–
–
–
–
–
–
–
Yes
–
–
(9)
(10)
(11)
AMG-232 (8)
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unlike Nutlin-3, representing a promising class of dual inhibi-
tors of these two proteins [26].
2.1.2. 5-member rings: pyrrolidine and pyrrole derivatives
Serious adverse effects observed in clinical trials for the imi-
dazoline-based compound RG7112, and relatively high doses
required to obtain a clinical effect have prompted the discov-
ery of RG7388 (5) (idasanutlin, RO5503781) (Figure 2) [27]. The
compound invented and disclosed by Hoffmann-La Roche,
presented much-improved activity in pre-clinical and clinical
studies, allowing for lower dosing schedules and resulting in
milder side effects. RG7388 is currently undergoing several
clinical examinations, including phase III clinical trial in combi-
nation with cytarabine for the treatment of relapsed and
refractory acute myeloid leukemia (AML) patients [22].
The structure of RG7388 was modified by the addition of
a polyethylene glycol solubilizing linker by the esterification of
the carboxylic group of the 3-methoxy benzoic acid, substituted
at the C-2 position of the pyrrolidine ring (6), as disclosed by
Hoffmann-La Roche in 2015 [29]. The compound was success-
fully used in combination with cytarabine in disseminated
MOLM-13 AML model in immunocompromised SCID-beige
mice, presenting more than additive therapeutic effects [29].
Similar polyethylene glycol linker was added to the structure of
RG7388 by the company Arivinas Inc. [30,31]. The modification,
however, went one step further resulting in the generation of bi-
functional drug candidates, that utilize a Proteolysis Targeting
Chimera (PROTAC) technology to target MDM2 protein for pro-
teasomal degradation (see section 2.5 for more details).
Bi-specific MDM2/MDMX inhibitors designed around the
5-membered ring core structure of 3-pyrrolin-2-on were
patented in 2015 by Adamed Sp. z o.o. (Table 1) [32]. The
core structure of the compounds is decorated with haloge-
nated aryl substituents (Figure 2), including 4-chlorophenyl
groups (7), characteristic also for bioactive representatives of
other classes of MDM2 antagonists, such as Nutlin-3 or AMG-
232. The activity of the compounds was monitored by the
fluorescence polarization (FP) assay, resulting in millimolar Ki
constants of MDM2/p53 disruption and millimolar Ki constants
of the disruption of MDMX/p53 complex.
2.1.3. 6-membered ring core structures – piperidinone and
morpholinone derivatives
In 2014 Amgen Inc. released a series of patents covering
structure optimization of previously reported 2-piperidinones,
and core-modified derivatives, morpholinones (Table 1) [33–
35]. Importantly, one of the representatives of 2-piperidinones,
AMG-232 (8) (Figure 3), is currently undergoing clinical trials
for the treatment of multiple myeloma, metastatic cutaneous
melanoma and acute myeloid leukemia patients [22].
The US 2014/0243372 patent claims the structure of only
one compound (9) which is highly similar to AMG-232 [33]. The
main difference is the introducing of the amide (from 4-amino-
2-metoxybenzoic acid) substituent instead of the acetic acid
moiety placed in the C-3 position of piperidinone ring (Figure
3). Other changes are at the N-substituent (replacement of
isopropyl group with cyclopropyl and tert-butyl) and C-6 phenyl
ring (additional fluorine atom at the 3-position of phenyl sub-
stituent). The remaining two patents by Amgen Inc. are focused
on morpholinone instead of piperidinone core [34,35]. The
examples presented in the patents cover a broad scope of
compounds designed around the morpholinone-cored AMG-
232-like general structure, with the optimization of substituents
leading to the best-performing representative compounds (10)
Figure 2. Structure and in vitro activity of exemplary MDM2 inhibitors based on 5 membered ring: pyrrolidine and pyrrole scaffolds. The IC50 value for RG7388 was is
from [28].
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from WO 2014/130470 and the (11) from WO 2014/151863
(Figure 3), as shown by the HTRF in vitro assay. The most
important characteristic feature of the compounds disclosed
in the patent WO 2014/130470 [34] is the 5,6-cis configuration
of the halogenated phenyl substituents, which is in the contrast
to the 5,6-trans configuration present in AMG-232 and other
two patents mentioned above [33,35]. Additional differences
are located all over the core structure, including C-5 and
C-6-phenyl substituents (e.g. various halogens, ethers, trifluor-
omethyl, indole.), N-1 substituent (shortened compered to
AMG-232, aliphatic or benzyl, including amide and others func-
tional groups), and exchange of C-2 acetic acid to other sub-
stituents (e.g. benzyl, alcohol, amine or aldehyde). Similar
substituent modifications, but with much lower diversity and
much fewer examples given, was covered by the patent WO
2014/151863 [35].
Additional Amgen Inc. patent from 2014 claims the process of
the production of AMG-232 compound and its intermediates,
securing the field of compound synthesis for any further clinical
use. This potential use includes various cancer treatments and
combinations with other drugs, such as inhibitors of PI3K, mTOR
or Akt [36]. In fact, several drug combinations involving AMG-232
compound and its derivatives were patented by Amgen Inc. in
a 2015 world patent [37] (see section 3 for more details).
2.2. Bicyclic core structures
Besides well exploited MDM2 antagonists designed around
a central, single ring core structures, additional scaffolds
were proposed, containing bicyclic cores. Among these
structures are: (i) 6 + 5-membered rings cores: purines, pyrro-
lopyrimidines, and isoindolinones from Merck Sharp & Dohme
Corp. and Astex Therapeutics Limited, (ii) 5 + 5-membered
rings cores: pyrazopyrrolidinones and imidazopyrrolidinon
from The Second Military Medical University and Novartis Ag,
respectively, and (iii) 6 + 6-membered rings cores – tetrahy-
dro-isoquinolin-3-ones from Novartis Ag (Table 2). From all
these classes, only two compounds owned by Novartis Ag,
namely HDM201 (5 + 5-membered rings core) and CGM097
(6 + 6-membered rings core), have entered clinical trials, so far.
Recently, Novartis has disclosed the invention related to the
dosing and regimen for the use of these molecules for the
treatment of hematological tumors [38,39].
2.2.1. Purine, pyrrolopyrimidine and isoindolinone
derivatives (6 + 5)
In 2014 Merck Sharp & Dohme Corp. have released three
world patents, covering a long list of MDM2 antagonists
built around the pyrrolo[3,2-d]pyrimidine [41] and purine
[42,43] cores (Table 2). In all the three patents multiple exam-
ples of compound modifications were presented, with some
clear trends in the substitution patterns [41]. Most commonly
the pyrrolo[3,2-d]pyrimidine core was substituted at carbons
atoms: C-2, C-4, C-6/C-7, and the nitrogen atom N-5, and
purine core at the corresponding carbon atoms C-2, C-6, C-8,
and the nitrogen atom N-7 (Figure 4). Similar trends are
observed in all patents, with the highest diversity of the tested
compounds presented in the case of 2,6,7,8-tetrasubstituted
purines [42]. First, from all of the introduced substituents, the
one placed at the C-2 position of the pyrrolo[3,2-d]pyrimidine
Figure 3. Structure and in vitro activity of exemplary MDM2 inhibitors based on 6 membered ring: piperidinone and morpholinone scaffolds. The IC50 value for AMG-
232 was is from [94].
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core (accordingly C-2 in purine) seems to be introduced in
order to increase solubility in a water medium. The substitu-
ents at the C-2 position are, among others: 4,5-dihydro-1,2,4,-
oxadiazol-5-one, carboxylic acid, tetrazole, sulphonamide, or
sulphoxide. The rest of the positions of the core rings are
decorated with the substituents characteristic also for many
other MDM2 inhibitors. Position C-4 (accordingly C-6 in purine)
is usually substituted with aliphatic amines (i.e. 1-cyclobuthy-
lethanamine, cyclohexylamine, benzylamine), aliphatic ethers
(i.e. 1-cyclobutylethoxyl), halogenated (chlorinated or fluori-
nated) phenyl, pyridine and others moieties (i.e. morpholine,
2-pyridone). At the position N-5 (accordingly N-7 in purine)
aromatic: phenyl or methylpyridine (substituted with i.e. halo-
gen atoms, trifluoromethyl, short aliphatic chain, and ethers),
or aliphatic rings (i.e. 4-methylcyclohexyl, spiro[2.5]octanyl) are
introduced. In all cases, the ring is separated from the mole-
cule core by the methylene group. Substitution at C-6 position
(accordingly C-8 in purine) was extensively studied, especially
with the purine core [42]. The substituents presented there
include aromatic rings directly attached to the C-6/C-8 carbon
atom (i.e. substituted phenyl, pyrimidine, imidazole), or
attached via a one-atom bridge (i.e. methylene, cyclopropyl).
Table 2. MDM2/X antagonists with bicyclic and multicyclic core structures.
Core structure Target
type of rings the core Assignee/patent No. (2014–2018) MDM2 MDMX Combination Examples
Compounds in clinical
trials
bicyclic
6 + 5-member
pyrrolopyrimidines
Merck Sharp & Dohme Corp.
WO 2014/100071 A2 [41] Yes – – (12) –
purine
Merck Sharp & Dohme Corp.
WO 2014/123882 A1 [43]
WO/2014/120748 A1 [42]
Yes
Yes
–
–
–
–
(13)
(14)
–
isoindolin-1-one
Astex Therapeutics Ltd.
WO 2017/055859 A1 [44]
WO 2017/055860 A1 [45]
Yes
Yes
–
–
–
–
(15)
(16)
–
5 + 5-member
pyrrolidonopyrazole
The Second Military Medical
University
WO/2014/134968 A1 [46]
Yes – – (17) –
pyrrolidonoimidazole
Novartis Ag
WO 2015/084804 A1 [47] Yes – Yes HDM201 (18)
6 + 6-member
dihydro-isoquinolin
-3-one
Novartis Ag
WO 2015/084804 A1 [47]
WO 2016/035023 A1 [85]
WO 2017/037586 A1 [86]
WO 2017/037579 A1 [87]
WO 2017/029588 A2 [88]
WO 2018/092064 A1 [89]
Yes
Yes
Yes
Yes
Yes
Yes
–
–
–
–
–
–
Yes
Yes
Yes
Yes
Yes
Yes
CGM097 (19)
multicyclic
acridine
Mirx Pharmaceuticals
US 2017/0022166 A1 [52] – Yes – (21) –
beta-carboline
Texas Tech
WO 2016/049453 A1 [81]
US 2017/0283413 A1 [40]
Yes
Yes
–
–
–
–
–
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Aromatic rings used were usually substituted with fluorine or
short aliphatic chains and ethers. Moreover, in this position
aliphatic rings (3-phenylmorpholine, cyclopropyl, octahydro-
4H-1,4-benzoxazine) were tested. Also, in this case, a one-
bond bridge was introduced and found in several examples.
Besides various ring structures, aliphatic chain substituents
with different functional groups (amines, alcohols, ethers)
can be found in the patents. Taking all this data together, in
all cases the substitutions are composed of at least one aro-
matic ring and one aliphatic, and when possible, a third ring,
being either aliphatic or aromatic. The activity of compounds
present in all the mentioned Merck Sharp & Dohme Corp.
patents was assessed by the fluorescence resonance energy
transfer assay (FRET). In the cases of pyrrolo[3,2-d]pyrimidine,
IC50 values start from several micromoles, and go down to low
nanomolar values, as for the exemplary compound (12), with
the most potent having IC50 below 1 nM. Generally, slightly
worse IC50 values were achieved by 2,6,7-trisubstituted pur-
ines [43], where the best binding example (13) had IC50 values
equal 21.58 nM. The best Mdm2 inhibitors from these patents
were examples of 2,6,7,8-tetrasubstituted purines, where for
multiple examples the IC50 value below 1 nM was reported , i.e
compound (14) with IC50 of 0.2019 nM (Figure 4). Altogether,
Merck Sharp & Dohme Corp present extensive structure-
activity relationship studies on the presented scaffolds, with
exceptionally good results and tremendous diversity of sub-
stitution pattern.
In 2017, Astex Therapeutics Ltd. has released two world
patents covering a large panel of the compounds, designed
around the central isoindolin-1-one core structure (Table 2)
[44,45]. The compounds possess a large diversity of substi-
tuents at several positions of the isoindolin-1-one bicycle,
including N-substitutions, and a featured double substitution
at the C-3 position (Table 1). This special double substitution
provides a stereo-geometry of the compound similar to the
geometry of spriro-oxindole compounds, that have been
extremely exploited by several leading companies in the
recent years (see section 2.4 for more details on spiro-
oxindole-based compounds). The C-3 bi-substitutions in all
the presented compounds are composed of one aromatic
substituent (4-chlorophenyl), and a short aliphatic chains or
rings, substituted with various functional groups such as
hydroxyl, amide, sulphonamide, or carboxyl, in some cases
even deuterated. The additional aromatic ring (phenyl, pyr-
idine or piperidine substituted usually with halogen, sulpho-
nyl, nitrile or short aliphatic ethers) is linked by a methylene
bridge at the N-2 position of the central ring. At the C-6
position, usually, aliphatic rings with a hydroxyl group are
introduced (i.e. 2-hydroxypropan-2-yl, 1-(4-fluorooxazn-4-yl)-
1-hydroxyethyl), although also several heterocycles were
tested (i.e. 1-methyl-1H-pyrazole-4-carbonyl). A small diver-
sity is presented in the case of the C-4 atom, which is almost
universally a fluorine atom. The resulting compounds cov-
ered by the Astex Therapeutics Ltd. patents have been
evaluated by an ELISA assay for testing of the blockade of
MDM2-p53 interaction. Most of the compounds, for which
ELISA results were reported in the patents WO 2017/055859
A1 [44] and WO 2017/055860 A1 [45] (almost 600 and 150
different compounds, respectively) presented IC50 values in
low nM range, with multiple individuals, exemplified by the
compounds (15, 16), having IC50 values around or even
below 1 nM. The activity of most of these hundreds of
compounds was further evaluated with the use of two
MDM2 amplified isogenic matched osteosarcoma cell lines,
SJSA-1 (with wild-type p53 status) and SN40R2 (p53-
mutated). The compounds presented excellent selectivity in
the two orthogonal cell viability assays performed (total
protein staining with SRB dye and CellTiter-Glo® assay), and
Figure 4. Structure and in vitro activity of exemplary MDM2 inhibitors based on bicyclic core (5 + 6): purine, pyrrolopyrimdine, isoindolinone scaffolds.
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high anti-cancer activities with IC50 values of SJSA-1 growth
inhibition going down to two-digit nM scale for the best-
performing representatives. Altogether, the data provided in
the patents confirm the successful development of isoindo-
lin-1-one MDM2 antagonists and justifies any further transi-
tion of this class of compounds to further pre-clinical trials.
2.2.2. Pyrrolidonopyrazoles and pyrrolidonoimidazoles
(5 + 5)
In the years 2014–2018 there were two patents covering
MDM2 antagonists that contain a 5 + 5 bicyclic core structure
(Figure 5). The first patent, assigned by The Second Military
Medical University in China presents an attempt to designing
MDM2-targeting compounds based on dihydropyrrolo[3,4-c]
pyrazol-6-one core structure (Table 2) [46]. The patent includes
around 25 compounds such as (17) tested in the biological
assays, presenting Ki values of the inhibition of p53-MDM2
interaction ranging from 0.06 to around 100 µM. Further
biological data is somehow confusing, as the given IC50 values
of the inhibition of the growth of p53wt and p53null cells
suggest no selectivity towards p53 compromised cancer
cells. Notably, since 2014 no additional structure optimization
has been patented by The Second Military Medical University,
suggesting that the project might have been closed.
Contrarily, a previous successful development of another
5 + 5 bicyclic-cored compound, HDM201 (18), based on the
dihydropyrrolo[3,4-d]imidazol-4-one core (Table 2), encouraged
its owner, Novartis Ag, to disclose its clinical use in combination
with B-Raf inhibitors [47] (see section 3 for more details on drug
combinations). Importantly, the HDM201 compound is one of
the few MDM2 antagonists, that have been progressed to the
clinical trials in recent years [22].
2.2.3. Dihydro-isoquinolin-3-one (6 + 6)
Dihydro-isoquinolin-3-ones (Table 2), the compounds with the
core structure composed of two 6-membered rings, were
exploited by the Novartis Ag company. The structure optimi-
zation process led to the discovery of CGM097 compound (19)
(Figure 5) [48], which presented excellent activity and in vivo
profile, and thus was directed to the evaluation in the clinical
trials [22]. Since then, the already optimal structure of CGM097
was not further developed. Instead, Novartis Ag has focused
on patenting the use of CGM097 in combinations with the
inhibitors of several additional therapeutic targets. For a more
detailed description of these therapeutic strategies see section
3 of this review article.
2.3. MDMX inhibitors
In the recent years, the importance of the design of dual inhibitors
of MDM2 and MDMX proteins got more and more attention.
Therefore, the compounds designed for MDM2 are routinely
checked also for their activity towards MDMX. Such an approach
is presented in several patents released in the years 2014–2018
[25,26,32,49–51]. From these, half patents concern peptidomi-
metics, though for macrocyclic peptides patented in 2016 by
Aileron Therapeutics Inc. no data confirming the claim about the
anti-MDMX activity is presented [50,51].
The other class of peptidomimetic molecules with MDMX-
antagonizing activity were published by the Agency for
Science, Technology and Research from Singapore as
a continuation of SAH-p53 peptides optimization [49]. The pre-
sented molecules have very good activity at low micromolar to
nanomolar range, both for MDM2 and MDMX. Most often the
activity towards MDMX is similar or only slightly weaker than it is
for MDM2, as exemplified for the peptide (20: sMTide-05), for
which the KD value measured by the T22 cell p53 β-galactosidase
assay is similar for MDMX (26.3 nM), and for MDM2 (29.9 nM).
The non-peptidomimetic dual MDM2/X antagonists
patented over the years 2014–2018 are based on either
3-pyrrolin-2-one [32], or cis-imidazolinone [25,26] scaffolds.
The activity of the 3-pyrrolin-2-one compounds, patented by
Adamed in 2015, is rather low compared to the other potent
MDM2/X antagonists. The described compounds were eval-
uated by TR-FRET method, and showed micro- to millimolar
Ki values, with around 10–100 times stronger inhibition
observed for MDM2, than for MDMX. The most optimal
antagonist (20) had Ki of 3.42 mM for MDMX and 0.38 mM
for MDM2 (Figure 6) [32].
Markedly better results were presented for cis-imidazoline
compounds. The patent presented in 2014 by Hoffman-La
Roche describes multiple examples of compounds with the
Figure 5. Structure and in vitro activity of exemplary MDM2 inhibitors based on bicyclic core (5 + 5 and 6 + 6): pyrrolidonopyrazole, pyrrolidonoimidazole, dihydro-
isoquinolin-3-one scaffolds. The IC50 value for CGM097 was is from [48].
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modified Nutlin-3a structure of 4,5-dimethyl-2-(3-sulfonylphe-
nyl)-4,5-diphenyl-imidazoline-1-carboxamide derivative with
the activity towards MDMX in low micromolar range [25].
Likewise, for other dual antagonists, the activity towards
MDM2 was significantly better than for MDMX, with the best
compounds active at low nanomolar range. This is repre-
sented by one of the most active compounds (3), for which
IC50 value of 4.8 nM for MDM2, and 193 nM for MDMX, as
assessed by the HTRF technique, was depicted.
The second patent disclosing cis-imidazoline compounds,
more specifically the substituted derivatives of 4-(2,4,5-triphenyli-
midazoline-1-carbonyl)piperazin-2-one, was presented by St. Jude
Children’s Research Hospital in 2015 [26]. The activity of these
compounds was evaluated by either FP or ITC, resulting in a low
micromolar range of KD forMDMX, and the values around 10 times
better forMDM2protein. As aprominent example, the compounds
(4) has the KD (ITC) 5.7 nM for MDM2 and 27 nM for MDMX.
Notably, in the reviewed years there was only one patent
application claiming the compounds developed specifically for
MDMX [52] The scaffold, disclosed by Mirx Pharmaceuticals, is
based on the substituted acridine (Table 2). Changeable substi-
tuents were mostly placed at C-3, C-6 and C-9 atoms of the
central heterocyclic core, with the C-3 and C-6 usually being
a nitro, amino or N-acetylamino group. The most variations
were placed on the C-9 position, with the versatile substituents
like halogen, nitrile, carboxylic acid, sulfonyl, azide or N-aryl (e.g.
phenyl, indole, thioindole, benzothiazole) amines. Most of the
examples were tested on the OCI cell line, resulting in IC50 values
ranging from over 15 μM to below 1 μM. From all the com-
pounds, the compound CTX1 (21) was the most studied, includ-
ing additional in vitro assays performed on several cell lines, and
in vivo examination usingNSGmice injectedwith primary human
acute myeloid leukemia cells. The improved survival of tumor-
bearing animals following the treatment with CTX1 may encou-
rage the grant assignee to provide further structure optimization
and progress to further pre-clinical studies.
2.4. Spiro-oxindoles
Since the initial design of spiro-oxindole compounds [53], they
became one of the most exploited and potent scaffolds for
MDM2 antagonists, with three prominent exemplary com-
pounds tested currently in several clinical trials. During the
last years, this scaffold was extensively tested and heavily
patented. Notably, all of the presented compounds possess
the 6-chloro substituent in the 2-oxindole (isoindolin-1-one)
core, which is consistent also with other MDM2 antagonist
classes and is justified by the anchoring character of 6-chlor-
oindole (Figures 7 and 8) (with the only one exception in the
2017 patent by King Saud University [54]).
2.4.1. Spiro-oxindoles with a 5-membered ring
The closest to the original design are the compounds dis-
closed in the three patents from 2015. The disclosed com-
pounds are based on the core structure of 6-chloro-spiro
[indoline-3,3ʹ-pyrrolidine]-2-one (Table 3, Figure 7). The first
patent, from Hudson Biopharma Inc., presents structure-
activity studies focused on the position C-2ʹ and C-5ʹ of pyrro-
lidine ring [55]. The C-5ʹ was substituted with carboxamide
(similarly to the previous potent compound, MI-77301 (22)
(SAR405838), derived from various anilines containing halogen
and/or carboxylic or amide group. The C-2ʹ was tested with
various short fluorinated aliphatic chains. In all cases at the
C-4ʹ position of the pyrrolidine ring, a 2-fluoro-3-chlorophenyl
group was introduced, which is characteristic for most of the
examples of spiro-oxindole MDM2 antagonists. The activity of
the presented compounds was assessed by TR-FRET method,
with the IC50 values at low nM range, exemplified by the
compound (23) with IC50 ≤ 3.6 nM.
The second group of compounds based on the structure
of 6-chloro-spiro[indoline-3,3ʹ-pyrrolidine]-2-one (Table 3,
Figure 7), was presented by the University of Michigan (The
Regents of the University of Michigan) in the two 2015
Figure 6. Structure and in vitro activity of exemplary MDMX inhibitors.
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patents [57,58]. Nine compounds showed in the patents
derive from a continued optimization of the MI-1061 struc-
ture (24), which is the second generation of the spiro-
oxindole derivatives with improved chiral stability of the
inhibitors, acquired by replacing the short aliphatic chain in
the C-2ʹ position to another spiro-structure (with cyclohex-
ane) [59]. The compounds present not only various new C-2ʹ
spiro-structures (substituted cyclohexanes) but mainly are
focused on replacing the C-5ʹ carboxamide, derived from
4-aminobenozic acid, to other benzoic acid bicyclic bioisos-
ters (i.e. bicycle [2,2]octane-1-carboxylic acid). The tested
compounds were tested for MDM2 inhibition (by the FP
assay and various cell-line analysis), and chiral stability of
the compound, with the final N-1ʹ-alkylated compound
demonstrating complete and persistent tumor regression in
mice bearing the SJSA-1 xenograft tumors (26; IC50
(FP) = 3.8 nM; IC50(SJSA-1) = 70 nM).
The last patent in this category of spiro-oxindole conjunct
with the 5-membraned ring was published also in 2015 by
Adamed Sp. z o.o., based on the tetrahydrospiro[indole-
3,2ʹpyrrole]-2,5ʹ-dione (Table 3, Figure 7) [60]. The compounds
present here seem to be the continuation of a previous patent
disclosed by this company, presenting structures built around
the 3-pyrrolin-2-one core (see secion 2.1.2). It is easily notice-
able that the introduction of 6-chloro-2-oxindole in the spiro
configuration to the scaffold makes the designed compounds
significantly more active than the original structures. The
examples shown in the patent could be subdivided into the
two separate classes: one with only 3-pyrrolin-2-one
(1ʹH-pyrrol-5ʹ-one), and the second with the bicyclic formation
of pyrrolo[3,4-c]pyrazole-6-one or pyrrolo[3,4-c]pyrrol-3-one.
Both classes have aromatic ring (usually halogenated phenyl
or pyridine) substituents at the N-1ʹ position of the 3-pyrrolin-
2-one ring. In the 1ʹH-pyrrol-5ʹ-one ring (numbering according
to the one used in the whole tetrahydrospiro[indole-3,2ʹpyr-
role]-2,5ʹ-dione structure), the C-4ʹ position is usually substi-
tuted with hydroxyl. The most prominent changes are present
in the C-3ʹ position which is tested with various short aliphatic
ketones, substituted phenyl attached directly or via a sulfide
bridge. In the second group of compounds, the C-3ʹ and C-4ʹ
substitutions were exchanged to a substituted ring (pyrazole
or pyrrole). The huge diversity of substitutions placed on this
Figure 7. Structure and in vitro activity of exemplary MDM2 inhibitors based on spiro-oxindoles connected with 5-membered ring: pyrrolidine and pyrrolinone. The
IC50 value for MI-77301 was is from [96] and for MI-1061 from [59].
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additional ring was tested, most commonly with two substi-
tuents, one of which was a short aliphatic chain (i.e. isopropyl),
and the second an aromatic ring. The activity of the com-
pounds was tested in the FP assay, and in SJSA-1 cell survival
study. Clearly the most potent compounds were those with
the pyrrolo[3,4-c]pyrazole-6-one or pyrrolo[3,4-c]pyrrol-3-one
ring, which is illustrated with the compounds (26) (one ring)
and (27) (two rings), exhibiting IC50(SJSA-1) = 21.4 μM/Ki
= 2.4 nM, and IC50(SJSA-1) = 0.53 μM/Ki = 4.7 nM, respectively.
2.4.2. Spiro-oxindole with a bicyclic fragment
In the years 2014–2018, four patents were published present-
ing bicyclic molecules attached to the 6-chloro-2-oxindole
structure. One of them, describing the pyrrolo[3,4-c]pyrazole-
6-one and pyrrolo[3,4-c]pyrrol-3-one rings [60], was a part of
the research on the tetrahydrospiro[indole-3,2ʹpyrrole]-2,5ʹ-
dione scaffold and was described in section 2.4.1.
The second, relatively short patent, was disclosed in 2017
by the King Saud University [54] and describes structures
based on the tetrahydro-3H’-spiro[indolin-3,5ʹ-pyrrolo[1,2-c]
thiazol]-2-one (Table 3). Probably, the requirements of the
synthesis led to compounds symmetrically substituted with
aryl component. One of the mentioned aryls was placed
directly at the C-7ʹ position of the pyrrolo[1,2-c]thiazol, and
the second at its C-6ʹ position via the acryloyl bridge. The
suitable aryls were chosen from a short list (total number of
around 20 compounds were tested), including substituted
phenyl (with various halogens, trifluoromethyl, methoxyl) or
heteroaryl (thiophene, furane). Interestingly, unlike in the
other patents describing spiro-oxindole scaffold, in the King
Saud University patent, the C-6 position of 2-oxindole was not
substituted. Moreover, in the case of relatively active com-
pound (28), the bromine atom was introduced in an unusual
C-5 position of the 2-oxindole core (Figure 8). All compounds
were tested on numerous human cell lines, including colon
cancer cells (HCT-116) and hepatocellular carcinoma cells
(HepG2), with overall activity in the low micromolar range.
The biggest effort in the case of the spiro-oxindoles
research was done by Boehringer Ingelheim International
Gmbh, with a total of four bulk patents on this subject
disclosed in the years 2014–2018. Three of them present
bicyclic cores, linked with 2-oxindole core via a spiro forma-
tion (Table 3, Figure 8) [61–63]. The first two describe mostly
the 6-chloro-hexahydro-1ʹH-spiro[indolin-3,2ʹ-pyrrolo[3,2ʹ-b]
pyrrol]-2one core, though also the 6-membered analogues
were disclosed (with hexahydro-pyrrolo[3,2-b]pyridine)
[61,62]. The latter patent describes quite similar compounds
[63]. The main scaffold is changed by introducing another
carbonyl group leaving the core of 6-chloro-hyexahydro
-4ʹH-spiro[indolin-3,2ʹ-pyrrolo[3,4-b]pyrrol]2,4ʹ-dione.
Significantly more examples of the 6-membered analogues
(with octahydro-pyrrolo[3,2-c]pyridine-4-one) can be found
throughout this patent. The substitution pattern presented
in structure-relationship studies of both patents is very simi-
lar. The substitutions at the N-1ʹ and C-3ʹ position of the
disclosed compounds were similar to the corresponding
positions in the MI-77301 compound (N-1ʹ: usually a short
aliphatic, less often a benzyl group; C-3ʹ: a halogenated phe-
nyl, usually the 2-fluoro-3-chlorophenyl). The largest diversity
was placed at C-5ʹ atom and N-4ʹ atom of a bicyclic fragment.
Most commonly, different versions of carboxylic acid or its
derivative (amide, ethyl ester) could be found, either of aro-
matic (i.e. 4-carboxyphenyl, benzyl, pyridine) or aliphatic
character. Other substitutions with known bioisosters of car-
boxylic acid could be found (tetrazole, sulfonyl). In all
Boehringer Ingelheim patents describing the MDM2 spiro-
oxinodle inhibitors the AlphaScreen (Amplified Luminescent
Proximity Homogeneous Assay) was used to validate com-
pounds activity. The resulting IC50 values were starting with
low micromolar for the weak compounds, going down to
2 nM for the most potent ones, as for the compounds (29)
and (30).
2.4.3. Spiro-oxindole with multicyclic fragments
The multicycle-containing spiro-oxindole derivatives were
disclosed solely by the Boehringer Ingelheim International
Gmbh as the continuation of the work on the scaffold with
bicyclic fragment (see section 2.4.2). In the two patents, the
multicycle fragment attached to the 6-chloro-2-oxindole is
composed of four different rings (Table 3, Figure 8) [64,65].
Like in the previous Boehringer Ingelheim patents, the sub-
stitutions around the first pyrrolidine ring (attached directly
through a sprio formation to the 6-chloro-2-oxindole) are
similar in both patents, and also similar to the general
trends observed for MI-compounds (like in the case of MI-
77301, see section 2.4.2). The most prominent changes here
were done by the introduction of a long pattern of cumu-
lated rings, which ends with the carboxylic group or other
similar groups (amide, ester, methylsulfonyl, halogen
atoms). The multicyclic formation is composed of pyrroli-
dine, aliphatic 5–7 membered ring (in the WO 2016/026937
A1 patent it is the tetrahydropyran or oxepane, while in the
WO 2017/060431 A1 patent it is the cyclopentane and
cyclohexane), a 5-membered heteroaromatic (WO 2016/
026937 A1 – pyrazole; WO 2017/060431 A1 – pyrazole or
imidazole), and, at the end, the substituted benzene (for the
sake of clarity the aliphatic rings were named without nitro-
gen, which is shared between them and heteroaromatic
ring). Disclosed patents described altogether a long list of
potential, highly active MDM2 inhibitors, with the activity of
the most potent compounds, represented by the IC50
values, reaching 2 nM in the AlphaScreen assay, as for the
exemplary compounds (31) with IC50 = 3 nM, and (32) with
IC50 = 2 nM.
2.5. The PROTAC technology utilizing MDM2 antagonists
Potent compounds targeting MDM2 are now utilized in
experimental cancer treatment strategies not only in
a classical way, using MDM2 antagonists as simple disruptors
of MDM2/p53 complexes, but also in the creation of so-called
PROTAC (Proteolysis Targeting Chimeric) compounds. PROTAC
technology was firstly discovered in early XXI century starting
a new chapter in small-molecule-driven inhibition of protein
targets for therapeutic use [66–68]. In general, PROTAC com-
pounds are composed of three distinguished parts: the frag-
ment with E3 ubiquitination ligase recognition ability, a small
molecule designed to selectively bind to the targeted protein,
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and the aliphatic linker, which couples both compounds to
create a single, bi-functional compound [69,70]. Thanks to this
bi-functionality, PROTAC compounds have the ability to recruit
ubiquitinating enzyme, an E3 ligase, to the target protein by
simultaneous binding of the two proteins. The recruited E3
ligase marks the targeted protein with a poly-ubiquitin chain,
directing the protein to proteasomal degradation, thus elim-
inating the molecular target.
PROTAC technology is highly patented, licensed by Arvinas
Inc. – a life-science company that originates from Yale
University. In the years 2015–2018 several patents by Arvinas
Inc. have been released, that utilize well-characterized com-
pounds with a strong MDM2 binding capability in a search for
therapeutic PROTAC probes (Figure 9).
In the initial patent, dated 2015 [30], the PROTAC technol-
ogy was used to attract a cereblon E3 ubiquitin ligase to a set
of therapeutic targets: androgen receptor (AR), estrogen
receptor (ER) α, bromodomain-containing protein 4 (BRD4),
TANK-binding kinase 1 (TBK1) and c-Myc. The proteins are
targeted by designing two-headed compounds composed of
target-interacting molecules, a linker, and a cereblon E3 ubi-
quitin ligase-binding ligand. This attraction of cereblon ligase
would lead to ubiquitination of protein targets and their
proteasomal degradation. Besides the tested interactions, the
patent covers the use of other molecular targets, including
MDM2 protein, for which nutlins have been proposed as
target-specific probes. However, because no bioactivity data
for the nutlin-directed cereblon-mediated degradation of
Figure 8. Structure and in vitro activity of exemplary MDM2 inhibitors based on spiro-oxindoles connected with multiple rings.
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Table 3. MDM2/X antagonists based on spiro-oxindole core structures.
Core structure Target
type of rings the core
Assignee/patent No.
(2014–2018) MDM2 MDMX Combination Examples
Compounds in
clinical trials
spiro-oxindole
5-member
pyrrolidine
Sanofi
EP 2 752 191 A1 [56]
Daiichi Sankyo
WO 2018/074387 A1 [91]
University of Michigan
WO 2015/161032 A1 [57]
US 2015/0299211 A1 [58]
Hudson Biopharma Inc.
US 2015/0322076 A1 [55]
Yes
Yes
Yes
Yes
–
–
–
–
Yes
Yes
–
–
(25)
(23)
MI-77301 (22)
APG-115
DS-3032b
3-pyrrolin-2-one
Adamed Sp. z o.o.
WO 2015/189799 A1 [60] Yes – – (26) –
bicyclic (5 + 5
member)
octahydropyrrolopyrrol
Adamed Sp. z o.o.
WO 2015/189799 A1 [60]
Boehringer Ingelheim
International Gmbh
WO 2015/155332 A1 [62]
Yes
Yes
–
–
–
–
(27)
(29)
–
hexahydropyrrolopyrrolone
Boehringer Ingelheim
International Gmbh
US 2015/0291611 A1 [61]
WO 2016/001376 A1 [63]
Yes
Yes
–
–
–
– (30)
–
pyrrolothiazole
King Saud University
US 9822128 B1 [54] Yes – – (28) –
multicyclic Boehringer Ingelheim
International Gmbh
WO 2016/026937 A1 [64]
Yes – – (31) –
X = N; Y, Z = C
Y = N; X, Z = C
Z = N; X, Y = C
Boehringer Ingelheim
International Gmbh
WO 2017/060431 A1 [65] Yes – – (32) –
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MDM2 is provided, the use of nutlins is somehow theoretical
in this patent.
In the following five patents by Arvinas Inc., MDM2 protein
is not only used as a therapeutic molecular target but also its
ubiquitinating properties are employed to target additional
proteins of therapeutic potential: BRD4 (33) [31], Androgen
Receptor (AR) (34) [31], c-Jun N-terminal kinases (JNK) [31],
Enhancer of Zeste Homolog 2 (EZH2) [31,71], ER [72,73], or
Rapidly Accelerated Fibrosarcoma (RAF) proteins [74].
Noteworthy, though the MDM2 ligase compounds are men-
tioned and claimed in all of the listed patents, the examples of
such compounds are rare. The coverage of MDM2 antagonist-
based PROTAC compounds is basically only presented in the
US 2017/0008904 A1 patent [31]. The examples presented
there are derivatives of Hoffmann-La Roche cis-imidazolines
(Nutlin-3a; RG7112) and pyrrolidine (RG7388, idasanutlin),
linked to the target-specific compounds. Importantly, the
designed compounds have the ability of both: (i) the induction
of p53-response characteristic for MDM2 antagonists, and (ii)
the degradation of PROTAC-targeted proteins (BRD4, AR, JNK
or EZH2), as exemplified by cell line data for the BRD4-
targeted compound [31]. The activity of the disclosed com-
pounds was assessed by a suitable cell-line analysis and the
results were categorized in three classes of activity, giving the
best result in the category of the degradation of the targeted
protein larger the 50% at 1 μM concertation. This simulta-
neous targeting of the two important cancer-related proteins,
namely p53 and BRD4, was recently shown by the Arvinas R&D
employees to give much improved results in in vitro cell line-
based assays, as compared with a corresponding VHL-utilizing
PROTAC with similar potency and efficacy to degrade
BRD4 [75].
It is worth mentioning, that the five above-mentioned
patents cover the use of almost every known potent MDM2
antagonist in the PROTAC technology, living very limited
space for any competitors in the field of medicinal chemistry.
Recently, the spectrum of uses of PROTAC technology for
addressing of the target proteins for proteasomal degradation
was broaden even further with the new WO patent by Arvinas,
Inc. [76]. Given the promising results of the initial in vitro
experiments based on the PROTAC technology, and the high
attention given to disclosing any possible drug conjugates, we
can expect more therapeutic uses and Arvinas patents cover-
ing MDM2 antagonists coming out in the nearest future.
2.6. Peptide derivatives
Peptide derivatives are another class of molecules, engineered
to provide drug candidates for the treatment of cancers by
blocking of protein-protein interactions. In a case of a MDM2-
p53 system, initially p53-derived peptides were utilized in
attempts to block the interaction between these two mole-
cules. Soon it became clear, that stabilization of peptides by
molecule cyclization provides improved activities due to sev-
eral effects, including increased cell penetration, stability and
target affinity [77].
Figure 9. Structure and activity of exemplary compounds utilizing PROTAC technology and MDM2 E3 ligase activity.
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In 2014 and 2015, the Agency for Science, Technology and
Research from Singapore patented a group of staple peptide-
inhibitors of MDM2-p53 interaction [49,78]. The peptides
sequences were selected based on a phage display technol-
ogy. Both, the WO [49] and the US [78] patents cover the same
bunch of compounds and present the same results to support
their in vitro activity. In fact, the presented stapled peptides
interact with MDM2, as exemplified by the crystal structure of
MTide-1 compound bound to MDM2 protein. At higher doses,
the peptides also induce the expression of p53 and its target,
MDM2 protein, but this effect can be observed only in the
absence of Fetal Bovine Serum. Additionally, the peptides
inhibit the growth of cancer cell lines by the induction of
cell cycle arrest, but the selectivity towards p53wt HCT116
cells in comparison to p53null HCT116 cells is very limited. No
further optimization of the stapled peptides by the Agency for
Science, Technology and Research has been patented in the
next years.
In 2016, the Aileron Therapeutics Inc. company has secured
the field of MDM2-antagonizing peptidomimetic macrocycles
in the two world patents [50,51]. By combining both natural
and artificial amino acids and different chemical linkers the
patents covered a huge spectrum of modifications of the
selected active peptide sequences. The in vitro results, exem-
plified for SP-154 and SP-763 compounds, show an excellent
selectivity of the peptides towards p53wt cells in cell viability
assay [51]. Importantly, one representative of the peptidomi-
metic macrocycles family disclosed by Aileron Therapeutics
Inc., the compound named ALRN-6924, is currently under-
going Phase 1/Phase 2 clinical evaluation for the treatment
of solid tumors, lymphoma and peripheral T-cell lymphoma
(ClinicalTrials.gov Identifier: NCT02264613). Besides the list of
potential therapeutics, the patents of Aileron Therapeutics Inc.
present dosing schemes and toxicology assessments, resulting
from the Phase 1 clinical trials [50,51].
One last patent, presenting peptide-based probes specific
for the MDM2, was released in 2018 by the Sorrento
Therapeutics Inc [79]. The MDM2-targeting peptide is linked
via a dibenzylocyclooctyl (DBCO) click chemistry reagent and
an ethyleneglycolphosphoramidite linker with a short nucleo-
tide sequence (35) (Figure 10). Such a construction of the
probe is said to provide cell permeability, preserving the p53-
inducing potential, as presented by the NanoBRET technology
in the transfected HeLa cells [79]. The patent represents an
innovative approach to targeting MDM2-p53 interaction in
living cells, but more in vitro and in vivo validation is required
to fully judge on its therapeutic potential.
Another approach to peptidomimetic compounds was
shown by the researchers from New York University [80]. The
patent from 2015 describes the development and character-
ization of oligo-oxopiperazine compounds. The structure was
designed, modeled with MDM2 protein and optimized with
Rosetta algorithm in order to mimic the three p53 amino acids
crucial for MDM2 binding (Phe19, Trp23, Leu27). The initial
screening led to the synthesis of 20 dimeric oxopiperazines –
with four amino acid side chains included, and 2 trimeric
oxopiperazine – with six amino acid side chains. The com-
pounds were tested against MDM2 with the Fluorescence
Polarization assay, revealing the best binding properties of
(O-Me)Tyr-Trp-Phe-Leu (example 17 in [80]), and 3-ClPhe-Trp-
Phe-Leu (36) (example 18 in [80]), with KD equal to 0.32 and
0.33 μM, respectively. The binding of the latter was addition-
ally tested by HSQC-NMR (heteronuclear single quantum
coherence) titration methodology.
2.7. Fused multicyclic compounds
Several patents described cumulated multicyclic structures
with MDM2/X-binding activity. Most of them are based on
the spiro-oxindole scaffolds (see Section 2.4). Another example
of such compounds are acridine derivatives with moderate
MDMX activity (see Section 2.3). The last one describes the
beta-caboline-based compounds claimed in 2016 by Texas
Tech University System [81] (Table 2).
Figure 10. Exemplary peptide inhibitors of MDM2/X protein.
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3. MDM2 antagonists in drug combinations
Following the successful development of the optimized, active
and safe MDM2 antagonists, several pharmaceutical compa-
nies, such as Hoffmann-La Roche, Amgen Inc., and Novartis,
have stopped further structure optimization trials of their lead
compounds. Instead, the companies have progressed for the
patents covering positive effects of combinations of these
drugs with additional therapeutic treatments.
In 2014, Hoffmann-La Roche patented the use of nutlin-3 in
a combination with CD20 antibodies for the treatment of
CD20-expressing cancers [82]. The use of nutlin-3 in combina-
tion with obinutuzumab (GA101, afucosylated type II anti-CD
20 antibody B-HH6-B-KV1 GE) or rituximab (RTX) provided
much improved in vivo antitumor activity than monotherapy
[82]. Each of the treatments alone resulted in only a partial
control over the growth of human Z138 mantle cell lymphoma
xenografts in SCID beige mice, while anti-CD20 treatments
combined with 150 mg/kg nutlin-3 orally administered 3
times weekly completely blocked the growth of xenografts.
A similar combination of GA101 with a new generation MDM2
antagonist RG7388 was patented by the Hoffmann-La Roche
in 2016 [83]. Again, the treatment of mice, bearing DOHH-2
human diffuse large B-cell lymphoma xenografts, with the
combination of 30 mg/kg RG7388 (oral administration) with
obinutuzumab provided an improved control over the tumor
growth and much improved survival rate [83,84]. The pre-
clinical success of the MDM2 antagonists/anti-CD20 combina-
tion strategy has encouraged Hoffmann-La Roche to proceed
to the clinical trials with the treatment of Relapsed/Refractory
Follicular Lymphoma patients with RG7388 and obinutuzu-
mab, or Relapsed/Refractory Diffuse Large B-Cell Lymphoma
patients with RG7388 and rituximab (ClinicalTrials.gov
Identifier: NCT02624986). The study has finished the recruit-
ment, but the results have not been posted yet.
In addition to anti-CD20 treatment, the 2016 patent
Hoffmann-La Roche proposes one additional combination,
targeting anti-apoptotic Bcl-2 protein with the use of veneto-
clax (GDC-0199) [83]. Not only the combination of RG7388
with venetoclax provided improved control over the tumor
growth in a mice xenograft model, but was also able to
decrease the initial tumor volume suggesting a successful
tumor eradication by the drug combination. Moreover, the
triple combination of RG7388, venetoclax and obinutuzumab
resulted in tumor eradication and 100% of animal survival over
the period of 130 days of the study [83]. Again, the corre-
sponding clinical trial for the treatment of Relapsed/Refractory
Acute Myeloid Leukemia patients with the combination of
RG7388 and venetoclax has been launched in 2016 and is
during the recruitment process (ClinicalTrials.gov Identifier:
NCT02670044).
Another beneficial combination dedicated to RG7388, that was
patented in 2015, was the combination with cytarabine (cytosine
arabinoside, ara-C) [29]. Cytarabine is an antimetabolite used in
a chemotherapyof leukemiapatients. The treatment of SCID-beige
mice bearing MOLM-13 AML xenografts with cytarabine alone did
not bring any therapeutic effects, while the treatment with an
esterified derivative of RG7388 inhibited the growth of tumors.
The combination of both compounds potentiated the therapeutic
effect of the treatment with MDM2 antagonists, suggesting posi-
tive modulatory effects of cytarabine on the outcome of the treat-
ment with the MDM2 antagonist [29]. With time, the use of
cytarabine became a favored strategy for the combined cancer
treatments with MDM2 in the clinical trials. The most advanced
program is the treatment of Relapsed or Refractory Acute Myeloid
Leukemia with RG7388 and cytarabine, that is sponsored by
RG7388 owner, Hoffmann-La Roche (ClinicalTrials.gov Identifier:
NCT02545283). This treatment regime has reached phase 3 of
clinical trials and is now recruiting patients for the 3.5 years overall
survival study. Besides RG7388, multiple additional MDM2 antago-
nists are involved in completed or recruiting clinical trials in com-
bination with cytarabine, including RG7112 (NCT01635296), MK-
8242 (NCT01451437), DS-3032b (milademetan, NCT03634228) and
ALRN-6924 (NCT03654716).
Another two big companies that put much effort into test-
ing and patenting positive drug interactions of their lead
MDM2 antagonists were Amgen Inc. and Novartis. First, in
a single patent from 2015, Amgen Inc. has reported a broad
screening of drug combinations of the lead MDM2 antagonist,
AMG-232, with a panel of anticancer drugs [37]. The combina-
tions were first tested in vitro with the use of multiple different
cell lines, and synergistic effects were calculated based on cell
viability CellTiter-Glo (Promega) and ATPLite (Perkin Elmer)
assays. Then, the selected treatments were used in in vivo
tumor xenograft studies, utilizing nude mice bearing the xeno-
grafts of appropriate cancer cells. Altogether, the reported
in vivo studies comprised the combinations of AMG-232
with: (a) MEK inhibitor AMG 1009089 in RKO, A375sq2 and
MOLM-13 xenografts, (b) B-Raf inhibitor AMG 2112819 in RKO
and A375sq2 xenografts, (c) cisplatin in H460 and HCT-116
xenografts, (d) doxorubicin in SJSA-1 and MOLM-13 xeno-
grafts, (e) topoisomerase-1 inhibitor irinotecan (CPT-11) in
HCT-116 xenografts, (f) cytarabine in MOLM-13 xenografts,
(g) tyrosine protein kinases inhibitor sorafenib in MOLM-13
xenografts, (h) 5-aza-2ʹ-deoxycytidine (decitabine) in MOLM-
13 xenografts, (i) PI3K inhibitor AMG 2520765 in U87 xeno-
grafts, and finally (j) double and triple combinations with B-Raf
inhibitor AMG 2112819, and PI3K inhibitor AMG 2539965 in
RKO xenografts [37]. Almost every reported drug combination
provided improved anticancer effects as compared to single
treatments, justifying the amenability of these drug interac-
tions for testing in clinical trials. In fact, three clinical trials
involving combined treatment with AMG-232 and MEK 1/2
inhibitor trametinib, with B-Raf inhibitor dabrafenib, or with
dexamethasone are currently in the patient recruitment stage
(NCT02016729, NCT02110355, and NCT03031730). In addition,
dexamethasone is evaluated also in combination with RG7388
from Roche (NCT02633059), trametinib with HDM201 from
Novartis (NCT03714958), and pimasertib, another MEK 1/2
inhibitor has been tested in combination with SAR405838
(NCT01985191).
In the years 2015–2018 Novartis was successively patenting
a series of drug combinations of CGM097 compounds with
therapeutics, targeting B-Raf protein [47], tyrosine kinase (nilo-
tinib) [85], PI3K [86], MEK [87], Bcl-2 [86,87], PKC [88], and Bcl-
xL [89]. From this list, synergistic effects of CGM097 with B-Raf
inhibitor, MEK inhibitor, Bcl-2 inhibitor, and PKC inhibitor have
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been verified in in vivo mice models, where combined treat-
ments presented much improved anticancer effects than
monotherapies [47,87,88]. For the other combinations, only
cell-based in vitro assays were performed and the in vivo out-
comes remain to be evaluated.
In a single patent by the University of the Science of
Philadelphia, a unique protein entity is presented, that pro-
vides simultaneous modulation of the activity of several can-
cer-related targets. The protein is composed of the MDM2-
binding peptide, linked via a caspase cleavage sequence with
either a whole human serum albumin or its fragments, that
retain the fatty acid (FA)-binding capability [90]. The patent
assignee claims that such a protein provides good transport of
MDM2-antagonizing peptide to the cell, and can be used for
co-transportation of additional, FA-linked drugs, such as MTX,
for combined anticancer treatments [90]. Additionally, the
patent reports unexpected interaction and blockade of two
additional targets, Bcl-xL and MCL, by the pure protein entity,
without loading of FA-linked drugs. This observation, although
very interesting, requires additional experimental verification,
as for now the mechanism explaining this surprising action
remains elusive.
The recent patent by Daiichi Sankyo Ltd. covers the use of
their DS-3032 (milademetan) in combination with DNA
methyltransferase inhibitor (azacitidine) [91]. The drug combi-
nation has been tested in in vivo model using NOD-SCID mice
implanted with MOLM-13 cells. The combination of 50 mg/kg
of DS-3032 and 2.5 or 4 mg/kg of azacitidine provided 90%
tumor growth inhibition, compared to untreated control,
while single therapies allowed for 28% and 72% of growth
inhibition for azacytidine and DS-3032, respectively [91]. Along
with the Daiichi Sankyo Inc. patent the combination of DS-
3032 with azacitidine is currently undergoing clinical investi-
gation in acute myelogenous leukemia and high-risk myelo-
dysplastic syndrome patients, sponsored by Daiichi Sankyo
Inc. (NCT02319369).
4. Expert opinion
Since the discovery of the nutlins, first-in-class bioactive MDM2
antagonists, the structure optimization of imidazolines and the
discovery of additional chemical scaffolds led to the develop-
ment of extremely strong MDM2-binding and selective second
and third generation antagonists. These optimized compounds
are able to reactivate the wild-type p53 by antagonizing MDM2
and/or MDMX proteins, to selectively inhibit the growth of the
p53 wild-type cells and provide good control over the growth of
p53wt tumors in animal models. Importantly, in recent years,
several representative compounds have successfully passed
through pre-clinical studies and entered the clinical trials
(reviewed in [22], see also Tables 1–3). These include the
nutlin-3a derivative RG7112 [92] and its pyrrolidine relative,
RG7388 (idasanutlin) from Roche [27], the piperidinone com-
pound AMG-232 from Amgen [93,94], the bicyclic-core com-
pounds CGM097 and HDM201 from Novartis [48,95], three
spiroindolinone derivative compounds, SAR405838 from Sanofi
[96], APG-115 from Ascentage Pharma Group Inc [97]., DS-3032b
from Daiichi Sankyo [98], a multicyclic-core compound BI
907828 from Boehringer Ingelheim [99], and a stapled peptide
ALRN-6924 from Aileron Therapeutics [100]. Among these,
RG7388 (idasanutlin, RO5503781) is now most advanced, as it
has recently progressed to the phase III clinical trials in combi-
nation with cytarabine in patients with relapsed or refractory
acute myeloid leukemia [22].
Additionally, new classes of MDM2-antagonizing molecules
appear sporadically, employing both new chemistry and new
biochemical mechanisms of action. These new classes include
peptidomimetic compounds, such as stapled peptides, and
PROTAC compounds. The latter strategy, utilizing bi-specific
probes composed of MDM2 antagonists and the compounds
specific to additional, cancer-related molecular targets, pro-
vides very promising pre-clinical results and may contribute
much to the development of future anticancer therapies.
It has been initially believed, that the reactivation of p53 by
antagonizing MDM2 protein will alone be sufficient to eradi-
cate the p53wt cancers. However, in the past decade, the
growing evidence has undermined this hypothesis. While
antagonists of MDM2 provide good control over the prolifera-
tion of multiple p53wt cancer cell lines both in vitro and in vivo,
it is now clear that even more than 50% of p53wt cancer cells
fail to comply with this rule [101]. Additionally, only in a subset
of p53wt cells that respond to MDM2 antagonists, the apopto-
sis program is induced, allowing for the successful cancer cell
elimination [6,102,103]. Moreover, the induction of cell quies-
cence with limited cell elimination by apoptosis leads to the
selection of drug-resistant clones, as first shown for nutlin-3
[104–106], and then for the more recent, clinically-evaluated
MDM2 antagonists, such as SAR405838 [107,108], HDM201
[109] and RG7388 [110]. For this reasons, there is now a clear
trend for the design of drug combination studies that would
involve MDM2 antagonists. Such an approach gives a chance
to take an advantage of the growth-inhibitory potential of the
MDM2 antagonists against p53wt cells and provide additional
anti-cancer effects by targeting additional molecular targets,
such as CD20, MEK 1/2, B-Raf, TK, PI3K, Bcl-2 or Bcl-xL, or by
adding standard chemotherapy agents, such as doxorubicin
cytarabine or 5-aza-2ʹ-deoxycytidine. Around 30% of the ther-
apeutic patents on MDM2 antagonists that were disclosed in
the years 2014–2018 cover at least one drug combination
strategy for improved treatment of human cancers. These
combinations are provided by combining two chemical enti-
ties in the dosing scheme, or by the chemical conjugation of
the two entities, which results in bi-functional combinatorial
drugs. It seems clear, that now, when several excellent MDM2-
antagonizing, orally available and relatively safe compounds
have been developed, the discovery of positive drug interac-
tions will proceed and will result in new patents on the treat-
ment regimens for anticancer therapy.
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